← Back to Clinical Trials
Recruiting NCT07116460

NCT07116460 Cost Effective Air Filtration Intervention in Low-Income Housing to Reduce Asthma Morbidity

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07116460
Status Recruiting
Phase
Sponsor Columbia University
Condition Asthma Attack
Study Type INTERVENTIONAL
Enrollment 55 participants
Start Date 2026-01-30
Primary Completion 2028-04

Eligibility & Interventions

Sex All sexes
Min Age 7 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Austin Air Cleaner

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 55 participants in total. It began in 2026-01-30 with a primary completion date of 2028-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project will investigate the effectiveness of HEPA air cleaners in reducing indoor air pollution and improving asthma morbidity in children living in East Harlem, New York City (NYC). The study will be conducted over a 2-year period. Columbia University and Little Sisters of the Assumption Family Health Service (LSAFHS) will conduct an intervention study to evaluate the efficacy of using a cost-effective high-capacity high efficiency particulate air (HEPA) filter air cleaner to reduce airborne particulate matter (PM) in the homes of children with asthma and to reduce their asthma morbidity. The study will take place in East Harlem, a low-income neighborhood with high asthma prevalence. It will build on findings from prior Housing and Urban Development Lead and Healthy Homes Technical Studies (HUD LHHTS)-funded research, the experience of LSAFHS installing air cleaners in the homes of asthmatic children, and recent findings demonstrating the effectiveness of home air cleaners in reducing asthma morbidity. The investigators hypothesize that the cost-effective single air cleaner will substantially reduce PM exposure in the homes of asthmatic children and reduce airway inflammation and asthma morbidity. This study will use cutting-edge air sampling technology to continuously quantify and characterize indoor air pollutants in the home for one year, verify and incentivize compliance, and conduct repeated exhaled nitric oxide and pulmonary function tests before and throughout the year after the intervention. This cost-effective intervention can be easily and quickly implemented in homes in low-income, urban communities and easily transferred between homes if families move.

Eligibility Criteria

Inclusion Criteria: * Age 7-18 years * Asthma symptoms in the past 4 weeks * Resident in lower-income housing in NYC Northern Manhattan and South Bronx Exclusion Criteria: * Inability to successfully perform spirometry maneuver or FeNO test * Family planning to move in the next year

Contact & Investigator

Central Contact

Matthew S Perzanowski, PhD

✉ mp2217@cumc.columbia.edu

📞 (212) 305-3465

Principal Investigator

Matthew S Perzanowski, PhD

PRINCIPAL INVESTIGATOR

Columbia University

Frequently Asked Questions

Who can join the NCT07116460 clinical trial?

This trial is open to participants of all sexes, aged 7 Years or older, up to 18 Years, studying Asthma Attack. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07116460 currently recruiting?

Yes, NCT07116460 is actively recruiting participants. Contact the research team at mp2217@cumc.columbia.edu for enrollment information.

Where is the NCT07116460 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT07116460 clinical trial?

NCT07116460 is sponsored by Columbia University. The principal investigator is Matthew S Perzanowski, PhD at Columbia University. The trial plans to enroll 55 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology